Moreover, the observed longer survival benefits could also be due to the fact that four out of the nine studies that assess the association between PD-L1 expression and OS in this meta-analysis recruited limited-stage SCLC patients while the rest enrolled both limited- and extensive-staged SCLC patients. The gene discussed is CD274; the disease is small cell lung carcinoma.